The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Analysts covering Merck predict earnings growth of 17.6% in 2025 and an additional 10.4% increase in 2026. With shares currently trading at seven times forward 2025 earnings, Merck appears to be an ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US counterparts.